BindingDB logo
myBDB logout

150 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27876250 60 Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CHEBI Jagiellonian University Medical College
27480029 6 Exploring new scaffolds for angiotensin II receptor antagonism.EBI National Hellenic Research Foundation
26824643 69 Mimicking of Arginine by Functionalized N(┐)-Carbamoylated Arginine As a New Broadly Applicable Approach to Labeled Bioactive Peptides: High Affinity Angiotensin, Neuropeptide Y, Neuropeptide FF, and Neurotensin Receptor Ligands As Examples.EBI University of Regensburg
26988801 55 Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.EBI Jagiellonian University Medical College
26390077 42 Tactical Approaches to Interconverting GPCR Agonists and Antagonists.EBI University of Minnesota
26810314 12 Structural determinants of subtype selectivity and functional activity of angiotensin II receptors.EBI Uppsala University
26314922 2 Imidazopyridines as a source of biological activity and their pharmacological potentials-Infrared and Raman spectroscopic evidence of their content in pharmaceuticals and plant materials.EBI Wroclaw University of Economics
25699147 6 Interconversion of Functional Activity by Minor Structural Alterations in Nonpeptide AT2 Receptor Ligands.EBI Uppsala University
25313325 8 Saralasin and Sarile Are AT2 Receptor Agonists.EBI Universit£ de Sherbrooke
25254961 32 Optimized protein kinase C┐ (PKC┐) inhibitors reveal only modest anti-inflammatory efficacy in a rodent model of arthritis.EBI AbbVie Bioresearch Center
24625069 28 Structure-activity relationship studies toward the discovery of selective apelin receptor agonists.EBI UMR7200 CNRS/Universit£ de Strasbourg
23265881 49 Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-¿.EBI Pfizer Inc.
15509155 5 NO-sartans: a new class of pharmacodynamic hybrids as cardiovascular drugs.EBI Universit£ di Pisa
19757839 26 The replacement of His(4) in angiotensin IV by conformationally constrained residues provides highly potent and selective analogues.EBI Vrije Universiteit Brussel
9379447 20 Angiotensin analogues palmitoylated in positions 1 and 4.EBI Universit£ de Sherbrooke
 19 Substituted lactam biphenyltetrazoles as angiotensin II mediated antihypertensivesEBI TBA
 40 Synthesis and In Vitro evaluation of fused ring heterocyle-containing angiotensin II antagonists.EBI TBA
21413808 170 Synopsis of some recent tactical application of bioisosteres in drug design.EBI Bristol-Myers Squibb Pharmaceutical Research and Development
22931505 69 Chemokine receptor antagonists.EBI National Heart and Lung Institute
23010269 145 Discovery of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221) as a functional antagonist of the apelin (APJ) receptor.EBI Sanford-Burnham Medical Research Institute
22889560 16 The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: a concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butylimidazole derivatives.EBI University of Patras
22727371 22 Design, synthesis and biological activity of 6-substituted carbamoyl benzimidazoles as new nonpeptidic angiotensin II AT1 receptor antagonists.EBI School of Chemical Engineering& the Environment
22750010 30 Synthesis and biological evaluation of 4'-[(benzimidazole-1-yl)methyl]biphenyl-2-sulfonamide derivatives as dual angiotensin II/endothelin A receptor antagonists.EBI China Pharmaceutical University
20875743 90 Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: design, synthesis, and structure-activity relaEBI Pfizer Inc.
20493713 30 Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition.EBI Uppsala University
18318468 39 Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems.EBI Universit£ di Siena
17358051 13 Synthesis of a new class of druglike angiotensin II C-terminal mimics with affinity for the AT2 receptor.EBI Uppsala University
17004728 4 Design, synthesis, and incorporation of a beta-turn mimetic in angiotensin II forming novel pseudopeptides with affinity for AT1 and AT2 receptors.EBI Uppsala University
16220978 14 Angiotensin II pseudopeptides containing 1,3,5-trisubstituted benzene scaffolds with high AT2 receptor affinity.EBI Uppsala University
16220969 219 Designed multiple ligands. An emerging drug discovery paradigm.EBI Organon Laboratories
15943474 10 New selective AT2 receptor ligands encompassing a gamma-turn mimetic replacing the amino acid residues 4-5 of angiotensin II act as agonists.EBI Uppsala University
15537355 4 AT2-selective angiotensin II analogues containing tyrosine-functionalized 5,5-bicyclic thiazabicycloalkane dipeptide mimetics.EBI Uppsala University
15537354 14 Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist.EBI Uppsala University
7241506 40 New analgesic drugs derived from phencyclidine.EBI TBA
14761188 8 A selective AT2 receptor ligand with a gamma-turn-like mimetic replacing the amino acid residues 4-5 of angiotensin II.EBI Uppsala University
12773029 8 Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.EBI Technische Universit£t Darmstadt
10821712 18 Quantized surface complementarity diversity (QSCD): a model based on small molecule-target complementarity.EBI NeoGenesis, Inc.
8576904 78 Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.EBI DuPont Merck Pharmaceutical Company
8709104 10 Novel cyclic analogs of angiotensin II with cyclization between positions 5 and 7: conformational and biological implications.EBI Washington University
8410980 9 2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.EBI Abbott Laboratories
8340909 14 Excursions in drug discovery.EBI Merck Research Laboratories
 32 L-161,638: A potent AT2selective quinazolinone angiotensin II binding inhibitorEBI TBA
 17 (6-oxo-3-pyridazinyl)-benzimidazoles as potent angiotensin II receptor antagonistsEBI TBA
 17 1,4-substituted indoles: a potent and selective class of angiostensin II receptor antagonistsEBI TBA
 4 The syntheses and binding affinities of tools for the study of angiotensin AT2 receptorsEBI TBA
22264484 28 Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists.EBI Kyung Hee University
22309912 28 Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazole derivatives as nonpeptidic angiotensin II AT1 receptor antagonists.EBI Beijing Institute of Technology
21683484 8 Application of Ullmann and Ullmann-Finkelstein reactions for the synthesis of N-aryl-N-(1H-pyrazol-3-yl) acetamide or N-(1-aryl-1H-pyrazol-3-yl) acetamide derivatives and pharmacological evaluation.EBI INSERM
21557540 39 Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-¿.EBI Pfizer Inc.
21071232 78 Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.EBI The M. S. University of Baroda
20813948 63 Spiroindolones, a potent compound class for the treatment of malaria.EBI Swiss Tropical and Public Health Institute
20591666 66 A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.EBI Università degli Studi di Milano
20146480 8 The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1.EBI Universite de Sherbrooke
20079636 78 Synthesis and biological activities of novel indole derivatives as potent and selective PPARgamma modulators.EBI Centre de Recherches
 24 The design, binding affinity prediction and synthesis of macrocyclic angiotensin II AT1 and AT2 receptor antagonistsEBI TBA
 10 L-162,389: a potent orally active angiotensin II receptor antagonist with balanced affinity to both AT1 and AT2 receptor subtypesEBI TBA
 54 4,5-Dihydro-4-oxo-3H-imidazo[4,5-c]pyridines: potent arylacetic acid-derived AT1 antagonists with improved affinity for the AT2 receptorEBI TBA
 42 Balanced AT1 and AT2 angiotensin II antagonists. II. Potent 5 α-hydroxyacid imidazolyl biphenyl sulfonylureasEBI TBA
 17 AT1 selective angiotensin II antagonists with phenoxyphenylacetic acid as a biphenyl replacement part IEBI TBA
 60 The SAR of 6-(N-alkyl-N-acyl)-2-propyl-3-[(2′-tetrazol-5-yl)biphen-4-yl)methyl]-quinazolinones as balanced affinity antagonists of the human AT1 and AT2 receptorsEBI TBA
 54 α-Phenoxyphenylacetic acid derived angiotensin II antagonists with low nanomolar AT1/AT2 receptor subtype affinity (Part II)EBI TBA
 3 D and L-N-[(1-benzyl-1H-imidazol-5-yl)-alkyl]-amino acids as angiotensin II AT-1 antagonistsEBI TBA
 19 2,3,6-Substituted quinazolinones as angiotensin II receptor antagonistsEBI TBA
 8 Substituted 1,3-benzodioxole & 1,3-benzodithiole -2- carboxylates and their tetrazole analogs with potent binding affinity to the angiotensin II AT1 receptorEBI TBA
 56 Potent triazolinone-based angiotensin II receptor antagonists with equivalent affinity for both the AT1 and AT2 subtypesEBI TBA
 134 Development of angiotensin II antagonists with equipotent affinity for human AT1 and AT2 receptor subtypes.EBI TBA
 122 Balanced angiotensin II receptor antagonists. III. The effects of substitution at the imidazole 5-position.EBI TBA
 68 Balanced angiotensin II receptor antagonists. II.1,2 4-aminomethyl- and acylaminomethylimidazolesEBI TBA
 46 Balanced angiotensin II receptor antagonists. I. The effects of biphenyl “ortho”-substitution on AT1/AT2 affinitiesEBI TBA
 10 Synthesis and biological evaluation of the potent isoxazolidinyl angiotensin II receptor antagonist CL332,877 and its enantiomers.EBI TBA
 34 6-isoxazolinyl and isoxazolidinyl substituted quinazolinones as angiotensin II receptor antagonistsEBI TBA
 19 Imidazolinones as nonpeptide angiotensin II receptor antagonistsEBI TBA
 54 A new class of balanced AT1/AT2 angiotensin II antagonists: quinazolinone AII antagonists with acylsulfonamide and sulfonylcarbamate acidic functionalitiesEBI TBA
 36 Quinazolinone Biphenyl Acylsulfonamides: A potent new class of angiotensin-II receptor antagonistsEBI TBA
 50 Potent imidazole angiotensinII antagonists: acyl sulfonamides and acyl sulfamides as tetrazole replacementsEBI TBA
 21 Tetrahydroisoquinoline derivatives with AT2-specific angiotensin II reception binding inhibitory activityEBI TBA
 10 Evaluation of heterocyclic acid equivalents as tetrazole replacements in imidazopyridine-based nonpeptide angiotensin II receptor antagonistsEBI TBA
 11 Valsartan, a potent, orally active angiotensin II antagonist developed from the structurally new amino acid seriesEBI TBA
 12 A potent long-acting imidazole-5-acrylic acid angiotensin II AT-1 receptor antagonistEBI TBA
 8 Synthesis of new imidazo[1,2-b]pyridazine isosteres of potent imidazo[4,5-b]pyridine angiotensin II antagonistsEBI TBA
 22 Acidic phenols: a new class of potent nonpeptide angiotensin II receptor antagonistsEBI TBA
 24 Subtituted phenylthiophene benzoylsulfonamides with potent binding affinity to angiotensin II AT1 and AT2 receptorsEBI TBA
 42 Imidazo[4,5-b]pyridine-based AT1 / AT2 angiotensin II receptor antagonistsEBI TBA
 19 Triazolinones as nonpeptide angiotensin II antagonists. 2. discovery of a potent and orally active triazolinone acylsulfonamideEBI TBA
 10 Angiotensin II receptor antagonists containing a phenylpyridine element.EBI TBA
 1 4,5,6,7-Tetrahdryo-8-oxo-cycloheptimidazoles: a new class of potent non-peptide angiiotensin II receptor antagonistsEBI TBA
 45 Quinazolinones 2: QSAR and in vivo characterization of AT1 selective AII antagonistsEBI TBA
 23 Quinazolinones 1: design and synthesis of potent quinazolinone- containing AT1-selective angiotensin-II receptor antagonistsEBI TBA
 56 Synthesis and structure-activity relationships of a novel series of non-peptide AT2-selective angiotensin II receptor antagonistsEBI TBA
19447613 9 Nocathiacin analogs: Synthesis and antibacterial activity of novel water-soluble amides.EBI Merck Research Laboratories
17412584 26 Synthesis and biological activity of 2-alkylbenzimidazoles bearing a N-phenylpyrrole moiety as novel angiotensin II AT1 receptor antagonists.EBI China Pharmaceutical University
17125268 44 Selective angiotensin II AT2 receptor agonists: arylbenzylimidazole structure-activity relationships.EBI Uppsala University
17064065 6 Further studies on imidazo[4,5-b]pyridine AT1 angiotensin II receptor antagonists. Effects of the transformation of the 4-phenylquinoline backbone into 4-phenylisoquinolinone or 1-phenylindene scaffolds.EBI Università di Siena
16722631 87 An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.EBI Predix Pharmaceuticals Ltd.
14998339 22 First reported nonpeptide AT1 receptor agonist (L-162,313) acts as an AT2 receptor agonist in vivo.EBI Uppsala University
14761190 10 Recognition of privileged structures by G-protein coupled receptors.EBI Novo Nordisk A/S
12361407 4 Comparison of 3D structures and AT(1) binding properties of pyrazolidine-3,5-diones and tetrahydropyridazine-3,6-diones with parent antihypertensive drug irbesartan.EBI Université de Lille 2
12190306 14 Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
12113820 4 Novel human metabolites of the angiotensin-II antagonist tasosartan and their pharmacological effects.EBI Wyeth Research
10893306 21 Synthesis and pharmacological evaluation of new pyrazolidine-3, 5-diones as AT(1) angiotensin II receptor antagonists.EBI Université de Lille 2
9046346 1 Synthesis and structure-activity relationship of a new series of potent AT1 selective angiotensin II receptor antagonists: 5-(biphenyl-4-ylmethyl)pyrazoles.EBI J. Uriach & Cía, S.A.
8667363 1 Diphenylpropionic acids as new AT1 selective angiotensin II antagonists.EBI J. Uriach & Cia SA
8515427 19 Multiple binding modes for the receptor-bound conformations of cyclic AII agonists.EBI Washington University School of Medicine
8496939 100 Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles.EBI Merck Research Laboratories
8421274 27 Nonpeptide angiotensin II antagonists: N-phenyl-1H-pyrrole derivatives are angiotensin II receptor antagonists.EBI Searle & Company
8355255 103 Triazolinones as nonpeptide angiotensin II antagonists. 1. Synthesis and evaluation of potent 2,4,5-trisubstituted triazolinones.EBI Merck Research Laboratories
8277506 58 Non-peptide angiotensin II receptor antagonists. 2. Design, synthesis, and biological activity of N-substituted (phenylamino)phenylacetic acids and acyl sulfonamides.EBI Merck Research Laboratories
8277505 58 Non-peptide angiotensin II receptor antagonists. 1. Design, synthesis, and biological activity of N-substituted indoles and dihydroindoles.EBI Merck Research Laboratories
8258820 23 A novel series of selective, non-peptide inhibitors of angiotensin II binding to the AT2 site.EBI DuPont Merck Pharmaceutical Co.
8246245 26 (Dipropylphenoxy)phenylacetic acids: a new generation of nonpeptide angiotensin II receptor antagonists.EBI Merck Research Laboratories
8246227 57 Nonpeptide angiotensin II antagonists derived from 1H-pyrazole-5-carboxylates and 4-aryl-1H-imidazole-5-carboxylates.EBI Merck Research Laboratories
8230109 18 A potent, orally active, balanced affinity angiotensin II AT1 antagonist and AT2 binding inhibitor.EBI Merck Research Laboratories
8201597 10 Non-peptide angiotensin II receptor antagonists: synthesis and biological activity of a series of novel 4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridine derivatives.EBI E. Merck
8064808 202 Triazolinone biphenylsulfonamide derivatives as orally active angiotensin II antagonists with potent AT1 receptor affinity and enhanced AT2 affinity.EBI Merck Research Laboratories
8057285 44 Synthesis and SAR studies of novel triazolopyrimidine derivatives as potent, orally active angiotensin II receptor antagonists.EBI Carpibem
7990105 16 A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.EBI Merck Research Laboratories
7799397 86 Triazolinone biphenylsulfonamides as angiotensin II receptor antagonists with high affinity for both the AT1 and AT2 subtypes.EBI Merck Research Laboratories
7636854 22 Balanced AT1/AT2 receptor antagonists. 4. XR510 and related 5-(3-amidopropanoyl)imidazoles possessing equal affinity for the AT1 and AT2 receptors.EBI DuPont Merck Pharmaceutical Company
7629811 19 Novel angiotensin II receptor antagonists. Design, synthesis, and in vitro evaluation of dibenzo[a,d]cycloheptene and dibenzo[b,f]oxepin derivatives. Searching for bioisosteres of biphenylyltetrazole using a three-dimensional search technique.EBI Shionogi & Co., Ltd.
7562906 3 Derivatives of 5-[[1-(4'-carboxybenzyl)imidazolyl]methylidene]hydantoins as orally active angiotensin II receptor antagonists.EBI Warner-Lambert Company
7562905 258 Potent and orally active angiotensin II receptor antagonists with equal affinity for human AT1 and AT2 subtypes.EBI Merck Research Laboratories
2016730 14 1-(carboxybenzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists.EBI SmithKline Beecham Pharmaceuticals
1433184 18 Discovery of a novel class of orally active, non-peptide angiotensin II antagonists.EBI Abbott Laboratories
15131245 86 SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.BDB Sanofi-Synthelabo Recherche
12721338 61 N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties.BDB Pudue Pharma Discovery Research
12570021 16 Binding of KRH-594, an antagonist of the angiotensin II type 1 receptor, to cloned human and rat angiotensin II receptors.BDB Shinshu University
11082453 77 ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse.BDB Abbott Laboratories
9454810 72 SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.BDB Sanofi Recherche
8996185 121 Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.BDB Synthélabo Recherche
7891350 9 Pharmacologic characterization of CI-996, a new angiotensin receptor antagonist.BDB Parke-Davis Pharmaceutical Research
7853174 25 In vivo receptor occupancy of the angiotensin II receptor by nonpeptide antagonists: relationship to in vitro affinities and in vivo pharmacologic potency.BDB Merck Research Laboratories
7562467 11 Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, U-97018.BDB Upjohn Pharmaceuticals Limited
7518514 46 (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization.BDB Abbott Laboratories